Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PREDIX HER2 Trial: Similar Efficacy, Less Toxicity with T-DM1 for HER2+, HR+ Breast Cancer

Publish date:: July 18, 2019

Key clinical point: T-DSM1 had similar efficacy, less toxicity vs. standard chemotherapy for HER2- and HR-positive breast cancer.

Major finding: The pCR rates were 45% and 47% with T-DM1 and DTP, respectively.

Study details: The phase 2 PREDIX HER2 trial of 199 patients.

Disclosures: Dr. Bergh reported a financial relationship with UpToDate, and research funding to his institution from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, and Sanofi.

Citation:

Bergh J et al. ASCO 2019, Abstract 501.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Study: Doctors underreport side effects of breast irradiation,

No edge for anastrozole over tamoxifen in DCIS,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Omitting postop radiotherapy doesn’t affect survival in older breast cancer patients,